Cytoskeleton-associated membrane protein 4 is upregulated in tumor tissues and is associated with clinicopathological characteristics and prognosis in hepatocellular carcinoma

Chen,Zhi-Yong; Wang,Ting; Gan,Xia; Chen,Si-Hai; He,Yu-Ting; Wang,Yu-Qi; Zhang,Kun-He

doi:10.3892/ol.2020.11499

Cytoskeleton-associated membrane protein 4 is upregulated in tumor tissues and is associated with clinicopathological characteristics and prognosis in hepatocellular carcinoma

Authors:
- Zhi-Yong Chen
- Ting Wang
- Xia Gan
- Si-Hai Chen
- Yu-Ting He
- Yu-Qi Wang
- Kun-He Zhang
View Affiliations

Affiliations: Department of Gastroenterology, The First Affiliated Hospital of Nanchang University, Jiangxi Institute of Gastroenterology and Hepatology, Nanchang, Jiangxi 330006, P.R. China
Published online on: March 31, 2020 https://doi.org/10.3892/ol.2020.11499
Pages: 3889-3898
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The role of cytoskeleton‑associated membrane protein 4 (CKAP4) in hepatocellular carcinoma (HCC) is controversial. The present study aimed to investigate the association between tumor CKAP4 mRNA expression and clinicopathological characteristics and prognosis in patients with HCC. Data relating to CKAP4 mRNA expression in HCC tumor and normal adjacent liver tissues, and clinicopathological characteristics, were downloaded from the Gene Expression Omnibus and The Cancer Genome Atlas databases. The CKAP4 mRNA levels in tumor tissues were compared with those in normal adjacent liver tissues, their association with clinicopathological parameters was analyzed, and diagnostic and prognostic values were evaluated in patients with HCC. In all 4 datasets (total samples, n=693), CKAP4 mRNA levels were significantly higher in tumor tissues compared with adjacent tissues (all P<0.001), with the area under the receiver operating characteristic curve ranging from 0.799‑0.898 for HCC diagnosis. In patients with HCC with available clinical data (n=361), the low‑level CKAP4 mRNA group exhibited a lower body mass index (P=0.005), higher α‑fetoprotein level (P<0.001), more frequent adjacent liver tissue inflammation (P<0.001), poorer tumor histological grade (P<0.001), higher Ishak fibrosis score (P=0.035) and a more advanced tumor node metastasis (TNM) stage (P=0.014) compared with the high‑level CKAP4 mRNA group. Patients stratified by all the above parameters, except for TNM stage, exhibited significantly different expression of tissue CKAP4 mRNA (P<0.05‑0.001). Furthermore, higher CKAP4 mRNA levels were observed in patients who died within one year following diagnosis compared with those who survived >3 years (P=0.003). The high‑level CKAP4 mRNA group also exhibited lower overall survival (OS) and disease‑free survival (DFS) rates compared with the low‑level group [hazard ratio (HR)=1.494; 95% confidence interval (CI), 1.044‑2.138; P=0.028] for OS and (HR=1.616; 95% CI, 1.022‑2.555; P=0.040) for DFS. The results of the present study suggest that CKAP4 mRNA is upregulated in HCC tumor tissues compared with normal adjacent tissues, and is associated with poor clinical prognosis, pathological features and survival in patients with HCC. Thus, CKAP4 is a potential biomarker for HCC diagnosis and prognosis.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
2	Global Burden of Disease Liver Cancer Collaboration, ; Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, Allen C, Al-Raddadi R, Alvis-Guzman N, Amoako Y, et al: The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: Results from the global burden of disease study 2015. JAMA Oncol. 3:1683–1691. 2017. View Article : Google Scholar : PubMed/NCBI
3	Shimada K, Sano T, Sakamoto Y and Kosuge T: A long-term follow-up and management study of hepatocellular carcinoma patients surviving for 10 years or longer after curative hepatectomy. Cancer. 104:1939–1947. 2005. View Article : Google Scholar : PubMed/NCBI
4	Poon RT: Prevention of recurrence after resection of hepatocellular carcinoma: A daunting challenge. Hepatology. 54:757–759. 2011. View Article : Google Scholar : PubMed/NCBI
5	Tralhao JG, Dagher I, Lino T, Roudie J and Franco D: Treatment of tumour recurrence after resection of hepatocellular carcinoma. Analysis of 97 consecutive patients. Eur J Surg Oncol. 33:746–751. 2007. View Article : Google Scholar : PubMed/NCBI
6	Aravalli RN, Steer CJ and Cressman EN: Molecular mechanisms of hepatocellular carcinoma. Hepatology. 48:2047–2063. 2008. View Article : Google Scholar : PubMed/NCBI
7	Gupta N, Manevich Y, Kazi AS, Tao JQ, Fisher AB and Bates SR: Identification and characterization of p63 (CKAP4/ERGIC-63/CLIMP-63), a surfactant protein A binding protein, on type II pneumocytes. Am J Physiol Lung Cell Mol Physiol. 291:L436–L446. 2006. View Article : Google Scholar : PubMed/NCBI
8	Schweizer A, Ericsson M, Bachi T, Griffiths G and Hauri HP: Characterization of a novel 63 kDa membrane protein. Implications for the organization of the ER-to-Golgi pathway. J Cell Sci. 104:671–683. 1993.PubMed/NCBI
9	Nikonov AV, Hauri HP, Lauring B and Kreibich G: Climp-63-mediated binding of microtubules to the ER affects the lateral mobility of translocon complexes. J Cell Sci. 120:2248–2258. 2007. View Article : Google Scholar : PubMed/NCBI
10	Shibata Y, Shemesh T, Prinz WA, Palazzo AF, Kozlov MM and Rapoport TA: Mechanisms determining the morphology of the peripheral ER. Cell. 143:774–788. 2010. View Article : Google Scholar : PubMed/NCBI
11	Bates SR, Kazi AS, Tao JQ, Yu KJ, Gonder DS, Feinstein SI and Fisher AB: Role of P63 (CKAP4) in binding of surfactant protein-A to type II pneumocytes. Am J Physiol Lung Cell Mol Physiol. 295:L658–L669. 2008. View Article : Google Scholar : PubMed/NCBI
12	Conrads TP, Tocci GM, Hood BL, Zhang CO, Guo L, Koch KR, Michejda CJ, Veenstra TD and Keay SK: CKAP4/p63 is a receptor for the frizzled-8 protein-related antiproliferative factor from interstitial cystitis patients. J Biol Chem. 281:37836–37843. 2006. View Article : Google Scholar : PubMed/NCBI
13	Shahjee HM, Koch KR, Guo L, Zhang CO and Keay SK: Antiproliferative factor decreases Akt phosphorylation and alters gene expression via CKAP4 in T24 bladder carcinoma cells. J Exp Clin Cancer Res. 29:1602010. View Article : Google Scholar : PubMed/NCBI
14	Kimura H, Fumoto K, Shojima K, Nojima S, Osugi Y, Tomihara H, Eguchi H, Shintani Y, Endo H, Inoue M, et al: CKAP4 is a Dickkopf1 receptor and is involved in tumor progression. J Clin Invest. 126:2689–2705. 2016. View Article : Google Scholar : PubMed/NCBI
15	Kikuchi A, Fumoto K and Kimura H: The Dickkopf1-cytoskeleton-associated protein 4 axis creates a novel signalling pathway and may represent a molecular target for cancer therapy. Br J Pharmacol. 174:4651–4665. 2017. View Article : Google Scholar : PubMed/NCBI
16	Shinno N, Kimura H, Sada R, Takiguchi S, Mori M, Fumoto K, Doki Y and Kikuchi A: Activation of the Dickkopf1-CKAP4 pathway is associated with poor prognosis of esophageal cancer and anti-CKAP4 antibody may be a new therapeutic drug. Oncogene. 37:3471–3484. 2018. View Article : Google Scholar : PubMed/NCBI
17	Johnston HE, Carter MJ, Larrayoz M, Clarke J, Garbis SD, Oscier D, Strefford JC, Steele AJ, Walewska R and Cragg MS: Proteomics profiling of CLL versus healthy B-cells identifies putative therapeutic targets and a subtype-independent signature of spliceosome dysregulation. Mol Cell Proteomics. 17:776–791. 2018. View Article : Google Scholar : PubMed/NCBI
18	Kimura H, Yamamoto H, Harada T, Fumoto K, Osugi Y, Sada R, Maehara N, Hikita H, Mori S, Eguchi H, et al: CKAP4, a DKK1 receptor, is a biomarker in exosomes derived from pancreatic cancer and a molecular target for therapy. Clin Cancer Res. 25:1936–1947. 2019. View Article : Google Scholar : PubMed/NCBI
19	Li SX, Tang GS, Zhou DX, Pan YF, Tan YX, Zhang J, Zhang B, Ding ZW, Liu LJ, Jiang TY, et al: Prognostic significance of cytoskeleton-associated membrane protein 4 and its palmitoyl acyltransferase DHHC2 in hepatocellular carcinoma. Cancer. 120:1520–1531. 2014. View Article : Google Scholar : PubMed/NCBI
20	Li SX, Liu LJ, Dong LW, Shi HG, Pan YF, Tan YX, Zhang J, Zhang B, Ding ZW, Jiang TY, et al: CKAP4 inhibited growth and metastasis of hepatocellular carcinoma through regulating EGFR signaling. Tumour Biol. 35:7999–8005. 2014. View Article : Google Scholar : PubMed/NCBI
21	Wang Y, Yu W, He M, Huang Y, Wang M and Zhu J: Serum cytoskeleton-associated protein 4 as a biomarker for the diagnosis of hepatocellular carcinoma. Onco Targets Ther. 12:359–364. 2018. View Article : Google Scholar : PubMed/NCBI
22	Cao Y, Ding W, Zhang J, Gao Q, Yang H, Cao W, Wang Z, Fang L and Du R: Significant down-regulation of urea cycle generates clinically relevant proteomic signature in hepatocellular carcinoma patients with macrovascular invasion. J Proteome Res. 18:2032–2044. 2019. View Article : Google Scholar : PubMed/NCBI
23	Ramalho FS, Ramalho LN, Della Porta L and Zucoloto S: Comparative immunohistochemical expression of p63 in human cholangiocarcinoma and hepatocellular carcinoma. J Gastroenterol Hepatol. 21:1276–1280. 2006. View Article : Google Scholar : PubMed/NCBI
24	Grinchuk OV, Yenamandra SP, Iyer R, Singh M, Lee HK, Lim KH, Chow PK and Kuznetsov VA: Tumor-adjacent tissue co-expression profile analysis reveals pro-oncogenic ribosomal gene signature for prognosis of resectable hepatocellular carcinoma. Mol Oncol. 12:89–113. 2018. View Article : Google Scholar : PubMed/NCBI
25	Wang H, Huo X, Yang XR, He J, Cheng L, Wang N, Deng X, Jin H, Wang N, Wang C, et al: STAT3-mediated upregulation of lncRNA HOXD-AS1 as a ceRNA facilitates liver cancer metastasis by regulating SOX4. Mol Cancer. 16:1362017. View Article : Google Scholar : PubMed/NCBI
26	Mah WC, Thurnherr T, Chow PK, Chung AY, Ooi LL, Toh HC, The BT, Saunthararajah Y and Lee CG: Methylation profiles reveal distinct subgroup of hepatocellular carcinoma patients with poor prognosis. PLoS One. 9:e1041582014. View Article : Google Scholar : PubMed/NCBI
27	Li MH, Dong LW, Li SX, Tang GS, Pan YF, Zhang J, Wang H, Zhou HB, Tan YX, Hu HP and Wang HY: Expression of cytoskeleton-associated protein 4 is related to lymphatic metastasis and indicates prognosis of intrahepatic cholangiocarcinoma patients after surgery resection. Cancer Lett. 337:248–253. 2013. View Article : Google Scholar : PubMed/NCBI
28	Desert R, Mebarki S, Desille M, Sicard M, Lavergne E, Renaud S, Bergeat D, Sulpice L, Perret C, Turlin B, et al: ‘Fibrous nests’ in human hepatocellular carcinoma express a Wnt-induced gene signature associated with poor clinical outcome. Int J Biochem Cell Biol. 81:195–207. 2016. View Article : Google Scholar : PubMed/NCBI
29	Huang Y, Yang X, Zhao F, Shen Q, Wang Z, Lv X, Hu B, Yu B, Fan J and Qin W: Overexpression of Dickkopf-1 predicts poor prognosis for patients with hepatocellular carcinoma after orthotopic liver transplantation by promoting cancer metastasis and recurrence. Med Oncol. 31:9662014. View Article : Google Scholar : PubMed/NCBI